If the OS data is perceived as good enough to gain approval, I would imagine we will see a nice pop. However, Ariad traditionally pulls back immediately after. So if there is a "trade" here, I would imagine it would be then.
Any thoughts from the board on the usual post Asco sector sell-off? All of my oncology bio's have had a nice run. I guess there should be some profit taking after the presentations.
It seems so obvious that I am a skeptic. I would like to keep at least half of my position for another year or so. WTF, it's been a 14 years since I started following this company, so why jump ship now!